HALO(Halozyme Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $443.31M | $660.12M | $829.25M | $1.02B | $1.40B |
| 毛利润 | $361.90M | $520.81M | $636.89M | $855.91M | $1.17B |
| 营业利润 | $275.90M | $267.53M | $337.57M | $551.48M | $469.01M |
| 净利润 | $402.71M | $202.13M | $281.59M | $444.09M | $316.89M |
| 经营现金流 | $299.44M | $240.11M | $388.57M | $479.06M | $651.56M |
| 自由现金流 | $297.98M | $235.30M | $373.28M | $468.37M | $644.59M |
| 摊薄每股收益 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |